Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences, Inc. reports clinical and corporate updates as a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders. Company news centers on roluperidone, its product candidate for negative symptoms of schizophrenia, including confirmatory Phase 3 activity, clinical safety data, pharmacokinetic and pharmacodynamic findings, and discussions related to trial design.
Recurring updates also cover financial results, research and development spending, private financing tied to the roluperidone program, investor and scientific conference participation, and governance changes. Minerva’s disclosures are focused on the development path for CNS product candidates rather than commercial product sales.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Minerva Neurosciences, Inc. (Nasdaq: NERV) reported its Q4 and full-year 2022 financial results and business updates. The company experienced a net loss of $6.7 million in Q4 2022, significantly down from a loss of $21.3 million in Q4 2021. The annual net loss was $32.1 million, compared to $49.9 million in 2021. Research and development expenses decreased to $3.2 million in Q4 from $18.7 million, largely due to a prior year impairment charge. Cash reserves were approximately $36.2 million as of December 31, 2022. The company remains focused on the regulatory path for its lead drug, roluperidone, which faced a Refuse to File letter from the FDA last fall, indicating ongoing dialogue with the agency.
Minerva Neurosciences (Nasdaq: NERV) announced it will release its fiscal year 2022 financial results and business updates on March 8, 2023. A conference call will follow on the same day at 8:30 a.m. Eastern Time. The company focuses on developing therapies for central nervous system disorders. Its product candidates include roluperidone for schizophrenia and MIN-301, currently in pre-clinical development for Parkinson’s disease. Details of the live webcast and subsequent archived session are available on the company’s website.